Physician profile
Rishikesh Morey
NPI 1043582703
$2,610.91
in general payments reported to CMS, 2019-2025
28 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $128 · 2021: $106 · 2022: $324 · 2023: $491 · 2024: $516 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Education: $96.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.06 |
| Education | $96.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $461.92 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $230.93 | 2019-2025 | |
| Amgen INC. | $179.41 | 2022-2025 | Tavneos, Krystexxa |
| Opko Pharmaceuticals, LLC | $160.54 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $154.85 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $125.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $123.16 | 2022-2023 | Xarelto |
| Horizon Therapeutics Plc | $118.64 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $118.55 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.48 | 2022-2025 | |
| Inspire Medical Systems, INC. | $107.01 | 2024 | Inspire |
| Ani Pharmaceuticals, INC. | $64.36 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $63.09 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $63.01 | 2023-2024 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $60.16 | 2022-2024 | Benlysta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $59.63 | 2019 | |
| Novo Nordisk INC | $58.84 | 2025 | Ozempic |
| Ultragenyx Pharmaceutical INC. | $57.99 | 2023-2024 | Crysvita |
| Ardelyx, INC. | $50.01 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $39.33 | 2022-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.68 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.27 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $24.06 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $22.30 | 2023 | Crysvita |
| Gilead Sciences, INC. | $22.04 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.89 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.96 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $18.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishikesh Morey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.